Literature DB >> 10464901

Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease.

M H Dewar1, A Jamieson, A McLean, G K Crompton.   

Abstract

Many patients with chronic obstructive airways disease (COAD) receive therapy by the inhaled route. This study was performed to assess whether patients with severe COAD could generate sufficient peak inspiratory flow (PIF) through Turbuhaler (Astra, Sodertalje) to operate it effectively. One hundred patients (45 men, 55 women, mean age 69.1 years) with COAD (mean (SD) duration 17.7 (16.3) years) and peak expiratory flow (PEF) < or = 200 l min-1 or forced expiratory volume in 1 sec (FEV1) < or = 1 litre were studied. A series of randomly assigned inspiratory and expiratory lung function tests were contiguously performed, using portable spirometers, within 48 h of a screening visit. An empty Turbuhaler was used in the study. The patients' normal medication was not restricted. Sixty-six patients were previous smokers, eight occasional smokers, 19 habitual smokers and seven had never smoked. Mean (SD) FEV1 was 0.7 (0.2) 1 and mean PEF was 182 (68) l min-1. All patients were able to generate PIF through Turbuhaler (PIF-T) of 28 l min-1 (mean 53; range 28-78 l min-1). Eighty-three patients generated PIF-T of > or = 40 l min-1. PIF-T correlated with PIF without Turbuhaler (r = 0.35), PEF (r = 0.3), FEV1 (r = 0.2) and forced vital capacity (FVC) (r = 0.23) although the relationships were too weak to be used to predict PIF-T. The results suggest that patients with severely limited lung function caused by COAD can operate Turbuhaler effectively.

Entities:  

Mesh:

Year:  1999        PMID: 10464901     DOI: 10.1016/s0954-6111(99)90316-5

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  9 in total

Review 1.  Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.

Authors:  Sohini Ghosh; Jill A Ohar; M Bradley Drummond
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-09-21       Impact factor: 2.849

2.  Evaluation of the use of inhaled medications by hospital inpatients with chronic obstructive pulmonary disease.

Authors:  Joshua Batterink; Karen Dahri; Amneet Aulakh; Carmen Rempel
Journal:  Can J Hosp Pharm       Date:  2012-03

3.  Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.

Authors:  L Pekka Malmberg; Paula Rytilä; Pertti Happonen; Tari Haahtela
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

4.  Reduced Peak Inspiratory Effort through the Diskus((R)) and the Turbuhaler((R)) due to Mishandling is Common in Clinical Practice.

Authors:  Andrea S Melani; Letizia S Bracci; Marcello Rossi
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

5.  Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.

Authors:  Wahida Azouz; Philip Chetcuti; Harold Hosker; Dinesh Saralaya; Henry Chrystyn
Journal:  BMC Pulm Med       Date:  2015-05-01       Impact factor: 3.317

6.  Peak inspiratory flow rate measurement by using In-Check DIAL for the different inhaler devices in elderly with obstructive airway diseases.

Authors:  Theerasuk Kawamatawong; Supattra Khiawwan; Prapaporn Pornsuriyasak
Journal:  J Asthma Allergy       Date:  2017-02-23

7.  Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD.

Authors:  Sohini Ghosh; Roy A Pleasants; Jill A Ohar; James F Donohue; M Bradley Drummond
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-03-01

Review 8.  What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape.

Authors:  Federico Lavorini; Christer Janson; Fulvio Braido; Georgios Stratelis; Anders Løkke
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

9.  Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World Data.

Authors:  Martin Anderson; Kathryn Collison; M Bradley Drummond; Melanie Hamilton; Renu Jain; Neil Martin; Richard A Mularski; Mike Thomas; Chang-Qing Zhu; Gary T Ferguson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-04-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.